Trial · NCT07083375
A Phase II Study of QL1706 With Anti-angiogenesis Therapy and Chemotherapy in Extensive-stage Small Cell Lung Cancer.
NCT07083375, Phase 2, Not yet recruiting, Zhijie Wang
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Phase II Study of QL1706 With Anti-angiogenesis Therapy and Chemotherapy in Extensive-stage Small Cell Lung Cancer. Trials, record NCT07083375. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07083375
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Phase II Study of QL1706 With Anti-angiogenesis Therapy and Chemotherapy in Extensive-stage Small Cell Lung Cancer.
- NCT number
- NCT07083375
- Status
- Not yet recruiting
- Phases
- Phase 2
- Enrollment
- 56 participants, estimated
- Lead sponsor
- Zhijie Wang
- Conditions
- Extensive Small Cell Lung Cancer
- Interventions
- QL1706 , bevacizumab, etoposide , cisplatin or carboplatin
- First posted
- 2025-07-24
- Last updated
- 2025-07-24
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Progression-Free Survival (PFS) | From enrollment to the end of monitoring at 2 years. | PFS is defined as the time from the first dose of study treatment to the first documentation of disease progression according to RECIST v1.1 (as assessed by investigators) or death from any cause, whichever occurs first. Subjects who are alive without progression at the time of analysis will be censored at the date of the last tumor assessment. |
| Secondary | Overall Survival (OS) | From enrollment to the end of monitoring at 2 years. | OS is defined as the time from the first dose of study treatment to death from any cause. Subjects who are alive at the time of analysis will be censored at the date of last follow-up. |
| Secondary | Objective Response Rate (ORR) | From enrollment to the end of monitoring at 2 years. | ORR is defined as the proportion of subjects who achieve a complete response (CR) or partial response (PR) as per RECIST v1.1. |
| Secondary | Duration of Response (DoR) | From enrollment to the end of monitoring at 2 years. | DoR is defined as the time from the first documentation of CR or PR to the first documentation of disease progression or death. |
| Secondary | Disease Control Rate (DCR) | From enrollment to the end of monitoring at 2 years. | DCR is defined as the proportion of subjects who achieve CR, PR, or stable disease (SD) as their best overall response. |
| Secondary | The incidence of adverse events | From enrollment to the end of monitoring at 2 years | Incidence, nature, and severity of adverse events (AEs), graded according to NCI-CTCAE v5.0, including immune-related AEs and serious AEs. |
| Other | Immune-Related Adverse Events (irAEs) | From enrollment to the end of monitoring at 2 years | Occurrence and grade of immune-related adverse events as defined by pre-specified criteria, including rash, colitis, hepatitis, endocrinopathies, and pneumonitis. |
| Other | Biomarker Analysis | From enrollment to the end of monitoring at 2 years | Tumor tissues were detected for PD-L1 using IHC. Potential biomarkers such as CD3+ and CD8+ were detected in peripheral blood. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers16
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07083375
GET https://conductscience.org/api/trials/v1/NCT07083375/registered